Kevin J Downes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7618/publications.pdf

Version: 2024-02-01

394421 377865 1,391 72 19 34 citations h-index g-index papers 76 76 76 1953 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Impact of Kinship Care on Behavioral Well-being for Children in Out-of-Home Care. JAMA Pediatrics, 2008, 162, 550.	3.0	156
2	Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 701-715.	1.3	130
3	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 34-48.	1.3	85
4	Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatrics, 2017, 171, e173219.	6.2	72
5	Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. International Journal of Antimicrobial Agents, 2014, 43, 223-230.	2.5	63
6	Mechanisms of antimicrobial-induced nephrotoxicity in children. Journal of Antimicrobial Chemotherapy, 2020, 75, 1 -13.	3.0	57
7	Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 629-634.	1.3	55
8	Vancomycinâ€Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. Pharmacotherapy, 2020, 40, 438-454.	2.6	51
9	How Long Does It Take to "Rule Out" Bacteremia in Children With Central Venous Catheters?. Pediatrics, 2008, 121, 135-141.	2.1	49
10	Polymicrobial Bloodstream Infections among Children and Adolescents with Central Venous Catheters Evaluated in Ambulatory Care. Clinical Infectious Diseases, 2008, 46, 387-394.	5.8	47
11	Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	46
12	Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease. Cell Host and Microbe, 2020, 28, 422-433.e7.	11.0	45
13	Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. Journal of Antimicrobial Chemotherapy, 2020, 75, 1228-1236.	3.0	43
14	Utility of Procalcitonin as a Biomarker for Sepsis in Children. Journal of Clinical Microbiology, 2020, 58, .	3.9	36
15	Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 435-441.	0.7	30
16	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVIDâ€19 Pandemic: Version 1. Arthritis and Rheumatology, 2020, 72, 1809-1819.	5.6	27
17	Clinical Features and Outcomes of Children with Culture-Negative Septic Arthritis. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 228-234.	1.3	26
18	Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clinical Pharmacokinetics, 2022, 61, 929-953.	3.5	25

#	Article	IF	Citations
19	Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 177-185.	1.3	23
20	Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis. Pediatric Nephrology, 2015, 30, 1879-1888.	1.7	22
21	Major Adverse Kidney Events in Pediatric Sepsis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 664-672.	4.5	21
22	Development and validation of a volumetric absorptive microsampling-liquid chromatography mass spectrometry method for the analysis of cefepime in human whole blood: Application to pediatric pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 113002.	2.8	21
23	Symptoms and Time to Medical Care in Children With Accidental Extremity Fractures. Pediatrics, 2012, 129, e128-e133.	2.1	19
24	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. Paediatric Drugs, 2020, 22, 165-188.	3.1	18
25	Return to School for Pediatric Solid Organ Transplant Recipients in the United States During the Coronavirus Disease 2019 Pandemic: Expert Opinion on Key Considerations and Best Practices. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 551-563.	1.3	17
26	A Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: The Optimizing Antibiotic Strategies in Sepsis (OASIS) Study. Journal of the Pediatric Infectious Diseases Society, 2017, 6, piw023.	1.3	16
27	Implementation of a Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II Study. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 36-43.	1.3	15
28	Acute Kidney Injury During Treatment with Intravenous Acyclovir for Suspected or Confirmed Neonatal Herpes Simplex Virus Infection. Journal of Pediatrics, 2020, 219, 126-132.e2.	1.8	15
29	Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Journal of Antimicrobial Chemotherapy, 2017, 72, 254-260.	3.0	14
30	Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. Applied Clinical Informatics, 2019, 10, 307-315.	1.7	11
31	Microsampling Assays for Pharmacokinetic Analysis and Therapeutic Drug Monitoring of Antimicrobial Drugs in Children. Therapeutic Drug Monitoring, 2020, Publish Ahead of Print, 335-345.	2.0	11
32	A whole blood microsampling assay for vancomycin: development, validation and application for pediatric clinical study. Bioanalysis, 2020, 12, 1295-1310.	1.5	10
33	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVIDâ€19 Pandemic: Version 2. Arthritis and Rheumatology, 2021, 73, e46-e59.	5.6	9
34	Vancomycin Prescribing and Therapeutic Drug Monitoring in Children With and Without Acute Kidney Injury After Cardiac Arrest. Paediatric Drugs, 2019, 21, 107-112.	3.1	8
35	CMV infection and management among pediatric solid organ transplant recipients. Pediatric Transplantation, 2022, 26, e14220.	1.0	8
36	Live virus vaccination following pediatric liver transplantation: Outcomes from two academic children's hospitals. American Journal of Transplantation, 2022, 22, 1201-1212.	4.7	8

#	Article	IF	CITATIONS
37	Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity. Clinical Pharmacology and Therapeutics, 2021, 109, 905-917.	4.7	7
38	The case for precision dosing: medical conservatism does not justify inaction. Journal of Antimicrobial Chemotherapy, 2021, 76, 1661-1665.	3.0	7
39	Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 43-54.	1.3	7
40	639. Short Course Therapy for Urinary Tract Infections (SCOUT) in Children. Open Forum Infectious Diseases, 2020, 7, S380-S380.	0.9	7
41	Guidelines for Management of Children With Fever and Neutropenia. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 281-285.	1.3	6
42	Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 199-218.	1.8	6
43	Practice Variation in Screening for Sexually Transmitted Infections with Nucleic Acid Amplification Tests During Prepubertal Sexual Abuse Evaluations. Journal of Pediatric and Adolescent Gynecology, 2009, 22, 292-299.	0.7	5
44	Posaconazole Administration in Hospitalized Children in the United States. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 481-484.	1.3	5
45	The use of echinocandins in hospitalized children in the United States. Medical Mycology, 2019, 57, 534-541.	0.7	5
46	The Pediatric Infectious Diseases Society Annual Awards, 2012. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 171-178.	1.3	3
47	Increased Vancomycin Exposure and Nephrotoxicity in Children: Therapeutic Does Not Mean Safe. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 65-67.	1.3	3
48	Precision dosing of vancomycin: in defence of AUC-guided therapy in children. Journal of Antimicrobial Chemotherapy, 2021, 76, 2494-2497.	3.0	3
49	Effect of Cystatin C on Vancomycin Clearance Estimation in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach. Therapeutic Drug Monitoring, 2020, 42, 848-855.	2.0	3
50	Biomarkers in Infectious Diseases. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 343-346.	1.3	2
51	The Cost of Vancomycin and Piperacillin/Tazobactam Treatment—Reply. JAMA Pediatrics, 2018, 172, 494.	6.2	2
52	Procalcitonin in Pediatric Sepsis: What Is It Good for?. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 1108-1110.	1.3	2
53	Revisiting the History: Hypereosinophilia in a 4-Year-Old With Purpura. Hospital Pediatrics, 2015, 5, 399-402.	1.3	1
54	Nonâ€typeable <i>Haemophilus influenzae</i> purulent pericarditis in a child with cystic fibrosis. Pediatrics International, 2016, 58, 607-609.	0.5	1

#	Article	IF	Citations
55	1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach. Open Forum Infectious Diseases, 2018, 5, S431-S432.	0.9	1
56	Continuous-Infusion Vancomycinâ€"Teaching an Old Dog New Tricks?. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e128-e130.	1.3	1
57	Liquid Chromatography-Tandem Mass Spectrometry Assays for Therapeutic Drug Monitoring of Cefepime. Journal of Applied Bioanalysis, 2018, 4, 144-156.	0.2	1
58	Biomarkers for Kidney Injury in Cystic Fibrosis. , 2016, , 689-718.		1
59	Fever and Upper Back Pain in a 15-year-old Boy. Pediatric Infectious Disease Journal, 2012, 31, 881.	2.0	0
60	Clostridium difficile Infection. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 83-86.	1.3	0
61	399Urinary NGAL is Elevated in Hospitalized Cystic Fibrosis Patients with Increased Tobramycin Exposure. Open Forum Infectious Diseases, 2014, 1, S1-S65.	0.9	0
62	Biomarkers for Kidney Injury in Cystic Fibrosis. , 2015, , 1-30.		0
63	Culture-Negative Septic Arthritis in Children. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
64	Antibiotic-Associated Acute Kidney Injury in Hospitalized Children. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
65	609. Acute Kidney Injury During Treatment with Intravenous Acyclovir (AKITA) for Suspected Neonatal Herpes Simplex Virus Infection. Open Forum Infectious Diseases, 2018, 5, S222-S222.	0.9	0
66	1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin–Tazobactam. Open Forum Infectious Diseases, 2019, 6, S483-S483.	0.9	0
67	Estimating renal function for drug dosing in critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome. Internal and Emergency Medicine, 2021, 16, 1751-1753.	2.0	0
68	572. Antiviral Toxicities Among Pediatric Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, S351-S351.	0.9	0
69	1396. Live Virus Vaccination Following Pediatric Liver Transplantation: Results from Two Academic Children's Hospitals. Open Forum Infectious Diseases, 2020, 7, S707-S708.	0.9	0
70	1104. Comparison of Antibiotic Sampling Techniques: Predicting Plasma Vancomycin Concentrations Using Volumetric Absorptive Microsampling (VAMS) from Capillary and Venous/Arterial Whole Blood. Open Forum Infectious Diseases, 2021, 8, S643-S644.	0.9	0
71	64. Novel Biomarkers Improve Estimation of Vancomycin Clearance in Critically Ill Children. Open Forum Infectious Diseases, 2021, 8, S43-S44.	0.9	0
72	A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation. Antimicrobial Agents and Chemotherapy, 2022, , e0237721.	3.2	0